SAN DIEGO, December 11, 2017 /PRNewswire/ --
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
"The patent application lists several dozen molecules that have a modulatory effect on NR2F6 seen across multiple assays," said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen. "In particular, we have included the unique structural element that we have identified as required for activation of NR2F6. Of course, we expect to continue to generate more unique small molecules, and we will file additional patent applications at the appropriate time."
"We continue to ensure that the intellectual property that is generated by Regen is protected so that our shareholders can materially benefit from the commercialization of this technology," said David Koos, Ph.D., CEO of Regen BioPharma, Inc.
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The company is focused on the immunology and immunotherapy space. The company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact Information Regen BioPharma Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer +1-619-702-1404 Phone +1-619-330-2328 Fax [email protected]
http://www.regenbiopharma.com SOURCE Regen BioPharma, Inc.
Advertisement
Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) today announced filing a patent application covering composition of matter and methods of use related to molecules identified in its small molecule program that activate and inhibit NR2F6 ("Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans").
Advertisement
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
"The patent application lists several dozen molecules that have a modulatory effect on NR2F6 seen across multiple assays," said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen. "In particular, we have included the unique structural element that we have identified as required for activation of NR2F6. Of course, we expect to continue to generate more unique small molecules, and we will file additional patent applications at the appropriate time."
"We continue to ensure that the intellectual property that is generated by Regen is protected so that our shareholders can materially benefit from the commercialization of this technology," said David Koos, Ph.D., CEO of Regen BioPharma, Inc.
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The company is focused on the immunology and immunotherapy space. The company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact Information Regen BioPharma Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer +1-619-702-1404 Phone +1-619-330-2328 Fax [email protected]
http://www.regenbiopharma.com SOURCE Regen BioPharma, Inc.
